Skip to content
The Nexus
DossierENTITY

epitalon

Coverage of epitalon in the Nexus archive.

Earliest in view: Jul 24 · 10:05 UTCMost recent: Jul 27 · 13:19 UTC
Co-mentioned in this coverage
Robert F. Kennedy Jr.person3emideltidetopic2U.S. Food and Drug Administrationorganization1Amgenorganization1Tavneostopic1Semaxtopic1Food and Drug Administration advisory panelorganization1peptidestopic1Social media influencerstopic1FDAorganization1BPC-157topic1TB-500topic1Peptide Industrytopic1Telehealth companiesorganization1
Recent coverage
  • HEALTHJul 27 · 13:19 UTCSTAT NEWS
    STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

    An FDA advisory panel recommended allowing compounding pharmacies to manufacture peptides epitalon and semax but voted against emideltide. Amgen is challenging the FDA's proposal to withdraw its drug Tavneos from the U.S. market, citing new evidence from over 70 real-world studies.

  • HEALTHJul 24 · 18:41 UTCSTAT NEWS
    FDA advisory panel narrowly rejects compounding of one peptide, back another

    An FDA advisory panel recommended allowing compounding pharmacies to manufacture the peptide epitalon but narrowly voted against emideltide. The decision brings health secretary Robert F. Kennedy, Jr. closer to expanding access to unapproved peptides, which have gained popularity through social media influencers.

  • HEALTHJul 24 · 10:05 UTCBUSINESS INSIDER
    Inside the unconventional FDA panel that could reshape the peptide industry

    An FDA advisory panel led by Robert F. Kennedy Jr. is reviewing seven banned therapeutic peptides, including BPC-157, TB-500, and epitalon, amid concerns over safety and efficacy. The two-day meeting (July 23-24) includes panelists with ties to peptide research, sales, or prescription, marking an unconventional approach to regulatory evaluation.